A Phase 1b Study of Talimogene Laherparepvec (T-VEC) in Combination With Paclitaxel or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-Negative Breast Cancer With Evidence of Injectable Disease in the Locoregional Area

Talimogene Laherparepvec With Paclitaxel or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer



Sponsors


Source

University of California, San Francisco

Oversight Info

Has Dmc

Yes

Is Fda Regulated Drug

Yes

Is Fda Regulated Device

No

Is Us Export

No


Brief Summary

This phase Ib trials studies the side effects and how well talimogene laherparepvec works
when given together with paclitaxel or endocrine therapy in treating participants with breast
cancer that does not express the human epidermal growth factor receptor 2 (HER2) protein and
has spread to other places in the body, cannot be removed by surgery, or has come back after.
Biological therapies, such as talimogene laherparepvec, use substances made from living
organisms that may attack specific tumor cells and stop them from growing or kill them. Drugs
used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Estrogen can cause the growth of breast cancer cells. Drugs used as endocrine
therapy, such as letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, may lessen the
amount of estrogen made by the body or may may stop the growth of tumor cells by blocking
estrogen from connecting to the cancer cells. Giving talimogene laherparepvec with paclitaxel
or endocrine therapy may work better in treating participants with HER2-negative breast
cancer.

Detailed Description

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability of intra-lesional talimogene laherparepvec
administration in combination with paclitaxel or endocrine therapy in patients with
metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer with
injectable sites of disease.

SECONDARY OBJECTIVES:

I. To evaluate the efficacy of talimogene laherparepvec in combination with paclitaxel in the
study population using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.

II. To evaluate the efficacy of talimogene laherparepvec in combination with endocrine
therapy in the study population using RECIST 1.1 criteria.

OUTLINE: Participants are assigned to 1 of 2 cohorts.

COHORT I (PACLITAXEL): Participants receive talimogene laherparepvec intra-tumorally (IT)
every 2 weeks for the first 12 weeks and then every 3 weeks thereafter. Participants also
receive paclitaxel intravenously (IV) over 60 minutes on days 1, 8, 15, and 22. Courses
repeat every 28 days in the absence of disease progression or unacceptable toxicity.

COHORT II (ENDOCRINE THERAPY): Participants receive talimogene laherparepvec IT every 2 weeks
for the first 12 weeks and then every 3 weeks thereafter. Participants also receive letrozole
orally (PO), anastrazole PO, exemestane PO, tamoxifen PO on days 1-28 or fulvestrant
intramuscularly (IM) every 2 weeks for 3 doses then every 4 weeks for the subsequent courses.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up for 30 days.

Overall Status

Not yet recruiting

Start Date

2018-12-11

Completion Date

2021-12-01

Primary Completion Date

2020-12-01

Phase

Phase 1

Study Type

Interventional

Primary Outcome

Measure

Time Frame

Distribution for the maximum observed grade for each adverse event of talimogene laherparepvec in both arms
Up to 2.5 years
Maximum tolerated volume defined as the highest volume (up to 4mL) that results in ≤ 1 dose limiting toxicity in 6 treated patients for each treatment cohort
Up to 2.5 years

Secondary Outcome

Measure

Time Frame

Overall response rate
From the start of the treatment until disease progression/recurrence (Up to 2.5 years)
Response duration
From initial response assessed up to 2.5 years

Enrollment

25

Conditions


Intervention

Intervention Type

Drug

Intervention Name


Description

Given PO

Arm Group Label

Cohort II (talimogene laherparepvec, endocrine therapy)

Other Name

Arimidex

ICI-D1033

ZD-1033



Intervention Type

Drug

Intervention Name


Description

Given PO

Arm Group Label

Cohort II (talimogene laherparepvec, endocrine therapy)

Other Name

Aromasin

FCE-24304



Intervention Type

Drug

Intervention Name


Description

Given IM

Arm Group Label

Cohort II (talimogene laherparepvec, endocrine therapy)

Other Name

Faslodex

ICI 182,780

ZD9238



Intervention Type

Drug

Intervention Name


Description

Given PO

Arm Group Label

Cohort II (talimogene laherparepvec, endocrine therapy)

Other Name

CGS 20267

Femara



Intervention Type

Drug

Intervention Name


Description

Given IV

Arm Group Label

Cohort I (talimogene laherparepvec, paclitaxel)

Other Name

Anzatax

Asotax

Bristaxol

Praxel

Taxol

Taxol Konzentrat



Intervention Type

Biological

Intervention Name


Description

Given IT

Arm Group Label

Cohort I (talimogene laherparepvec, paclitaxel)

Cohort II (talimogene laherparepvec, endocrine therapy)


Other Name

ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene

Imlygic

JS1 34.5-hGMCSF 47- pA-

T-VEC



Intervention Type

Drug

Intervention Name


Description

Given PO

Arm Group Label

Cohort II (talimogene laherparepvec, endocrine therapy)



Eligibility

Criteria

Inclusion Criteria:

- Metastatic or locoregionally recurrent HER2-negative breast cancer; resectable disease
allowed

- Ability to understand and voluntarily sign informed consent prior to undergoing any
study-related assessments or procedures, as well as adhere to the study visit schedule
and other protocol requirements

- Histologic or cytologic confirmation of invasive breast cancer that is HER2-negative
by standard clinical criteria

- Patients who will participate in the endocrine therapy cohort must have invasive
breast cancer that is estrogen receptor (ER)+ (>= 1% ER staining by
immunohistochemistry [IHC])

- At least one accessible and injectable lesion in the locoregional area (ie. breast,
chest wall, skin nodule or mass, axillary or supraclavicular lymph node) of at least 1
centimeter (cm); (ultrasound imaging may be used as clinically indicated)

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

- Concomitant use of bisphosphonates, receptor activator of nuclear factor kappa-B
ligand (RANKL) antibody, and ovarian suppression is allowed

- Absolute neutrophil count (ANC) ≥ 1.5x10^9/L for paclitaxel cohort, and ≥ 1.0x10^9/L
for endocrine therapy cohort

- Hemoglobin (Hgb) ≥ 9 g/dL

- Platelets (plt) ≥ 100 x 10^9/L for paclitaxel cohort, and ≥ 75, 000 for endocrine
therapy cohort

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper
limit normal (ULN)

- Serum total bilirubin ≤ 1.5 x ULN

- Serum creatinine ≤ 1.5 x ULN, or 24-hour (hr) clearance ? 60 ml/min

- International normalization ratio (INR) or prothrombin time (PT) ≥ 1.5 x

- Females of child-bearing potential (FCBP) should have a negative urine or serum
pregnancy test within 72 hours prior to enrollment; if urine test is positive or
cannot be confirmed as negative, a serum pregnancy test will be required; FCBP must
also be willing to adhere to acceptable forms of birth control (a physician-approved
contraceptive method: tubal ligation; intra-uterine device; barrier contraceptive with
spermicide; or vasectomized partner) during the study treatment and through 3 months
after the last dose of talimogene laherparepvec; FCBP are defined as sexually mature
women who:

- Have not undergone a hysterectomy (the surgical removal of the uterus) or
bilateral oophorectomy (the surgical removal of both ovaries) or,

- Have not been naturally postmenopausal for at least 12 consecutive months (i.e.
has had menses at any time during the preceding 12 consecutive months)

- Must be willing to practice abstinence or use effective contraception for a
minimum of 3 months following completion of study treatment (in addition to
during study therapy)

Exclusion Criteria:

- Any significant medical condition, laboratory abnormalities, which places the subject
at unacceptable risk if he/she were to participate in the study

- Any condition that confounds the ability to interpret data from the study

- Patients must have recovered from side effects resulting from prior cancer-directed
therapy to a level of grade 1 or less (unless deemed not clinically significant by
study investigator)

- Symptomatic central nervous system metastases; subjects with brain metastases that
have been previously treated and are stable for 4 weeks off steroids are allowed;
patients must be stable off steroids for brain metastases for at least 7 days;
subjects with asymptomatic clinically insignificant brain metastases not requiring
treatment are allowed; the exception does not include carcinomatous meningitis which
is excluded regardless of clinical stability

- Patients with leptomeningeal disease

- History of symptomatic autoimmune disease or active autoimmune disease that has
required systemic treatment in the 2 weeks prior to enrollment; replacement therapy
(e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for
adrenal or pituitary insufficiency, etc.) is not considered a form of systemic
treatment

- Evidence of immune suppression due to: a) known human immunodeficiency virus (HIV)
infection or acquired immunodeficiency syndrome (AIDS); b) known leukemia or lymphoma;
c) those who require high dose steroids (> 10 mg/day of prednisone or equivalent
within 7 days prior to enrollment) or other immunosuppressive therapies (> 2 weeks);
d) active hepatitis B or C; e) congenital or acquired cellular and/or humoral immune
deficiency; f) other signs or symptoms of immune system suppression or concurrent
opportunistic infection

- Paclitaxel arm: grade 2 or higher neuropathy

- Known history of: cardiac disease, heart failure or decreased left ventricular
ejection fraction, significant clinical arrhythmias

- Patients must not have received an investigational agent within 4 weeks or ? 5 half
lives, whichever is shorter, prior to starting study treatment

- Last dose of chemotherapy must be at least 3 weeks before first dose of study
treatment; there is no required washout for endocrine therapy

- Major surgery or radiation ≤ 2 weeks prior to starting study treatment or who have not
recovered from side effects of surgery or radiation

- Active herpetic skin lesions or prior complications of HSV-1 infection (e.g. herpetic
encephalitis or keratitis)

- Lesions with underlying infection or clinically meaningful bleeding

- Requires intermittent or chronic systemic (intravenous or oral) treatment with an
antiherpetic drug (e.g. acyclovir), other than intermittent topical use; patients
requiring anti-herpetic prophylaxis during chemotherapy are excluded

- Previous treatment with talimogene laherparepvec or any other oncolytic virus

- Prior therapy with tumor vaccine

- Received live vaccine within 28 days prior to enrollment

- Known allergic reaction to talimogene laherparepvec, paclitaxel, aromatase inhibitors,
tamoxifen, fulvestrant, or any of their components; an exception is made if the
patient will not be receiving the offending agent/component (i.e. a patient who is
allergic to paclitaxel but will be receiving endocrine therapy is eligible)

- Patients on therapeutic anticoagulation

- Women who are pregnant or breast-feeding

- FCBP who are unwilling to use acceptable method(s) of effective contraception during
study treatment and through 3 months after the last dose of talimogene laherparepvec

- Sexually active subjects and their partners unwilling to use a male or female latex
condom to avoid potential viral transmission during sexual contact while on treatment
and within 30 days after treatment with talimogene laherparepvec

- Subjects who are unwilling to minimize exposure with his/her blood or other body
fluids to individuals who are at higher risks for HSV 1 induced complications
(immunosuppressed individuals, HIV positive individuals, pregnant women, or children
under the age of 1 year) during talimogene laherparepvec treatment and through 30 days
after the last dose of talimogene laherparepvec

Gender

All

Minimum Age

18 Years

Maximum Age

N/A

Healthy Volunteers

No


Overall Official

Last Name

Role

Affiliation

Amy Chien
Principal Investigator
University of California, San Francisco

Location

Facility

Status

Contact

Investigator

University of California, San Francisco
San Francisco California 94115 United States
Not yet recruiting
Last Name: Amy J. Chien, MD
Phone: 877-827-3222
Email: [email protected]
Last Name: Amy J. Chien
Role: Principal Investigator

Location Countries

Country

United States


Verification Date

2018-05-01

Lastchanged Date

N/A

Firstreceived Date

N/A

Responsible Party

Responsible Party Type

Principal Investigator

Investigator Affiliation

University of California, San Francisco

Investigator Full Name

Jo Chien

Investigator Title

Associate Clinical Professor


Has Expanded Access

No

Condition Browse


Secondary Id

NCI-2018-00652

17-21623


Number Of Arms

2

Intervention Browse

Mesh Term

Paclitaxel

Letrozole

Fulvestrant

Exemestane

Anastrozole

Albumin-Bound Paclitaxel

Tamoxifen



Arm Group

Arm Group Label

Cohort I (talimogene laherparepvec, paclitaxel)

Arm Group Type

Experimental

Description

Participants receive talimogene laherparepvec IT every 2 weeks for the first 12 weeks and then every 3 weeks thereafter. Participants also receive paclitaxel IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.


Arm Group Label

Cohort II (talimogene laherparepvec, endocrine therapy)

Arm Group Type

Experimental

Description

Participants receive talimogene laherparepvec IT every 2 weeks for the first 12 weeks and then every 3 weeks thereafter. Participants also receive letrozole PO, anastrazole PO, exemestane PO, tamoxifen PO on days 1-28 or fulvestrant IM every 2 weeks for 3 doses then every 4 weeks for the subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.



Firstreceived Results Date

N/A

Firstreceived Results Disposition Date

N/A

Study Design Info

Allocation

Non-Randomized

Intervention Model

Parallel Assignment

Primary Purpose

Treatment

Masking

None (Open Label)


Study First Submitted

May 30, 2018

Study First Submitted Qc

May 30, 2018

Study First Posted

June 12, 2018

Last Update Submitted

June 29, 2018

Last Update Submitted Qc

June 29, 2018

Last Update Posted

July 2, 2018


ClinicalTrials.gov processed this data on August 31, 2018

Conditions

Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov, conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Interventions

Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied. Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Study Phase

Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions that study is seeking to answer:

In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.

In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.

In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.

These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.



© 2018 ICH GCP